Clinical Trial Update: Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports on patient preferences between subcutaneous and intravenous administration of trastuzumab (Herceptin) for HER2-positive early …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-06-08